Royal Bank Of Canada Galectin Therapeutics Inc Transaction History
Royal Bank Of Canada
- $471 Billion
- Q3 2024
A detailed history of Royal Bank Of Canada transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Royal Bank Of Canada holds 3,581 shares of GALT stock, worth $3,939. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,581
Previous 3,536
1.27%
Holding current value
$3,939
Previous $7,000
28.57%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding GALT
# of Institutions
91Shares Held
9.67MCall Options Held
1.16MPut Options Held
1.98M-
Vanguard Group Inc Valley Forge, PA2.13MShares$2.35 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$1.72 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.18MShares$1.3 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA863KShares$948,7960.0% of portfolio
-
Commonwealth Equity Services, LLC483KShares$531,5900.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $65.4M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...